Effect of bacterium in the malignant wounds of soft tissue sarcoma

Nakata,Eiji; Fujiwara,Tomohiro; Katayama,Haruyoshi; Itano,Takuto; Kunisada,Toshiyuki; Ozaki,Toshifumi

doi:10.3892/ol.2022.13465

Effect of bacterium in the malignant wounds of soft tissue sarcoma

Authors:
- Eiji Nakata
- Tomohiro Fujiwara
- Haruyoshi Katayama
- Takuto Itano
- Toshiyuki Kunisada
- Toshifumi Ozaki
View Affiliations

Affiliations: Department of Orthopedic Surgery, Okayama University Hospital, Okayama, Okayama 700‑8558, Japan
Published online on: August 17, 2022 https://doi.org/10.3892/ol.2022.13465
Article Number: 345
Copyright: © Nakata et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Malignant wounds (MWs) are rare skin lesions, which accompany ulceration, necrosis and infection caused by infiltration or damage by malignant tumor. The present study aimed to investigate the bacterial etiology implicated in MW in soft tissue sarcoma (STS), and the effectiveness of culture‑guided perioperative antibacterial administration. A retrospective evaluation was conducted on medical records of patients who presented with MW between 2006 and 2020. A total of seven patients were included in the present study, in whom all tumors were relatively large (>5 cm) and high‑grade. Subsequently, five patients underwent limb‑sparing surgery, and three patients had distant metastases with a 5‑year overall survival of 71%. Preoperative microbiological sampling from the wound identified 11 different bacterial strains in five patients. The infections were polymicrobial with an average of 2.6 strains isolated per patient (1 aerobic, 1.6 anaerobic bacteria). They were predominantly methicillin‑sensitive Staphylococcus aureus. Patients with MWs from STS reported symptoms, including bleeding (71%), exudation (71%) and malodorous wound (43%) at the initial presentation; these completely resolved after surgery. All but one patient reported pain at the MW site with an average numeric rating scale of 4.4 at presentation that decreased to 1.4 (P=0.14) and 0.6 (P=0.04) one and two weeks after surgery, respectively. The patients had elevated C‑reactive protein (71%), anemia (57%), low albumin (86%) and renal/liver dysfunction (14‑29%). One patient was diagnosed with sepsis. Surgical resection afforded symptomatic relief and resolution of abnormal laboratory values. Although selected antibiotics were administered in four patients based on the preoperative antibiotic sensitivity test, surgical site infection (SSI) occurred in three patients. Therefore, the effectiveness of the selected antibiotics based on the results of the preoperative culture in preventing SSI needs to be investigated in the future. In conclusion, physicians should keep in mind that although surgical resection can improve the symptoms and abnormal values in laboratory examination form MW, it is accompanied with a high rate of SSI and poor prognosis.

View Figures

View References

1	Alexander S: Malignant fungating wounds: Epidemiology, aetiology, presentation and assessment. J Wound Care. 18:273–274. 2009. View Article : Google Scholar : PubMed/NCBI
2	Alvarez O, Kalinski C, Nusbaum J, Hernandez L, Pappous E, Kyriannis C, Parker R, Chrzanowski G and Comfort CP: Incorporating wound healing strategies to improve palliation (symptom management) in patients with chronic wounds. J Palliat Med. 10:1161–1189. 2007. View Article : Google Scholar : PubMed/NCBI
3	Vardhan M, Flaminio Z, Sapru S, Tilley CP, Fu MR, Comfort C, Li X and Saxena D: The microbiome, malignant fungating wounds, and palliative care. Front Cell Infect Microbiol. 9:3732019. View Article : Google Scholar : PubMed/NCBI
4	Fromantin I, Seyer D, Watson S, Rollot F, Elard J, Escande MC, De Rycke Y, Kriegel I and Larreta Garde V: Bacterial floras and biofilms of malignant wounds associated with breast cancers. J Clin Microbiol. 51:3368–3373. 2013. View Article : Google Scholar : PubMed/NCBI
5	Finlayson K, Teleni L and McCarthy AL: Topical opioids and antimicrobials for the management of pain, infection, and infection-related odors in malignant wounds: A systematic review. Oncol Nurs Forum. 44:626–632. 2017. View Article : Google Scholar : PubMed/NCBI
6	Mohs FE, Sevringhaus EL and Schmidt ER: Conservative amputation of gangrenous parts by chemosurgery. Ann Surg. 114:274–282. 1941. View Article : Google Scholar : PubMed/NCBI
7	Mohs FE: Chemosurgical treatment of cancer of the extremities and trunk; a microscopically controlled method of excision. Arch Surg (1920). 57:818–832. 1948. View Article : Google Scholar : PubMed/NCBI
8	Nemoto K, Okamoto M, Kito M, Aoki K, Suzuki S, Takazawa A, Yoshimura Y and Kato H: Combined treatment using Mohs' paste and neoadjuvant chemotherapy for giant gluteal soft tissue sarcoma with malignant fungating wound: A case report. J Surg Case Rep. 2019:rjz1372019. View Article : Google Scholar : PubMed/NCBI
9	Hoshi M, Iwai T, Oebisu N and Nakamura H: Successful pre-operative local control of skin exposure by sarcoma using combination of systemic chemotherapy and Mohs' chemosurgery. World J Surg Oncol. 18:362020. View Article : Google Scholar : PubMed/NCBI
10	Bower M, Stein R, Evans TR, Hedley A, Pert P and Coombes RC: A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. Eur J Cance. 28A:888–889. 1992. View Article : Google Scholar : PubMed/NCBI
11	Kalinski C, Schnepf M, Laboy D, Hernandez L, Nusbaum J, McGrinder B, Comfort C and Alvarez OM: Effectiveness of a topical formulation containing metronidazole for wound odor and exudate control. Wounds. 17:84–90. 2005.
12	Ashford R, Plant G, Maher J and Teare L: Double-blind trial of metronidazole in malodorous ulcerating tumours. Lancet. 1:1232–1233. 1984. View Article : Google Scholar : PubMed/NCBI
13	Lutchminarian K and Clarke DL: The microbiology of ulcerative skin cancers: Does the presence of pathogenic bacteria increase the risk of postoperative complications? S Afr J Surg. 59:25a–25e. 2021. View Article : Google Scholar : PubMed/NCBI
14	Elfallal AH, Laimon YN and Emile SH: Giant angiolipoma of the back complicated with ulceration and sepsis: Unusual presentation of a rare benign tumour. Ann R Coll Surg Engl. 101:e91–e93. 2019. View Article : Google Scholar : PubMed/NCBI
15	Okajima K, Kobayashi H, Okuma T, Arai S, Zhang L, Hirai T, Ishibashi Y, Ikegami M, Shinoda Y, Akiyama T, et al: Prognosis and surgical outcome of soft tissue sarcoma with malignant fungating wounds. Jpn J Clin Oncol. 51:78–84. 2021. View Article : Google Scholar : PubMed/NCBI
16	Potter BK, Adams SC, Qadir R, Pitcher JD and Temple HT: Fungating soft-tissue sarcomas. Treatment implications and prognostic importance of malignant ulceration. J Bone Joint Surg Am. 91:567–574. 2009. View Article : Google Scholar : PubMed/NCBI
17	Parry M, Evans S, Sugath S, Wafa H, Jeys L and Grimer R: Fungation in soft tissue sarcomas is associated with poor survival. Int Orthop. 41:2613–2618. 2017. View Article : Google Scholar : PubMed/NCBI
18	Hoshi M, Oebisu N, Iwai T, Ieguchi M and Nakamura H: Clinical course of soft tissue sarcomas presenting as malignant wounds. J Orthop Sci. 24:1088–1093. 2019. View Article : Google Scholar : PubMed/NCBI
19	Fletcher CD, Bridge JA, Hogendoorn P and Mertens F: WHO Classification of Tumours of soft tissue and bone. 4th edition. IARC Press; Lion: 2013
20	Guillou L, Coindre JM, Bonichon F, Nguyen BB, Terrier P, Collin F, Vilain MO, Mandard AM, Le Doussal V, Leroux A, et al: Comparative study of the National cancer institute and french federation of cancer centers sarcoma group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol. 15:350–362. 1997. View Article : Google Scholar : PubMed/NCBI
21	Mangram AJ, Horan TC, Pearson ML, Silver LC and Jarvis WR: Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 20:250–278. 1999. View Article : Google Scholar : PubMed/NCBI
22	Egi M, Ogura H, Yatabe T, Atagi K, Inoue S, Iba T, Kakihana Y, Kawasaki T, Kushimoto S, Kuroda Y, et al: The Japanese clinical practice guidelines for management of sepsis and septic shock 2020 (J-SSCG 2020). J Intensive Care. 9:532021. View Article : Google Scholar : PubMed/NCBI
23	Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, Kumar A, Sevransky JE, Sprung CL, Nunnally ME, et al: Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016. Crit Care Med. 45:486–552. 2017. View Article : Google Scholar : PubMed/NCBI
24	Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, Rubenfeld G, Kahn JM, Shankar-Hari M, Singer M, et al: Assessment of Clinical criteria for sepsis: For the Third International consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 315:762–774. 2016. View Article : Google Scholar : PubMed/NCBI
25	Pandharipande PP, Sanders N, Jacques P, Ely EW and Shintani A: Calculating SOFA scores when arterial blood gasses are not available: Validating SpO₂/FIO₂ ratios for imputing PaO₂/FIO₂ ratios in the SOFA scores. Crit Care Med. 34:A12006. View Article : Google Scholar
26	Pasricha SR, Colman K, Centeno-Tablante E, Garcia-Casal MN and Peña-Rosas JP: Revisiting WHO haemoglobin thresholds to define anaemia in clinical medicine and public health. Lancet Haematol. 5:e60–e62. 2018. View Article : Google Scholar : PubMed/NCBI
27	Wittekind C, Compton C, Quirke P, Nagtegaal I, Merkel S, Hermanek P and Sobin LH: A uniform residual tumor (R) classification: Integration of the R classification and the circumferential margin status. Cancer. 115:3483–3488. 2009. View Article : Google Scholar : PubMed/NCBI
28	Zainul-Abidin S, Amanatullah DF, Anderson MB, Austin M, Barretto JM, Battenberg A, Bedard NA, Bell K, Blevins K, Callaghan JJ, et al: General assembly, prevention, host related general: Proceedings of International consensus on orthopedic infections. J Arthroplasty. 34:S13–S35. 2019. View Article : Google Scholar : PubMed/NCBI
29	Chauveaux D: Preventing surgical-site infections: Measures other than antibiotics. Orthop Traumatol Surg Res. 101 (Suppl 1):S77–S83. 2015. View Article : Google Scholar : PubMed/NCBI
30	Korol E, Johnston K, Waser N, Sifakis F, Jafri HS, Lo M and Kyaw MH: A systematic review of risk factors associated with surgical site infections among surgical patients. PLoS One. 8:e837432013. View Article : Google Scholar : PubMed/NCBI
31	Ramasubbu DA, Smith V, Hayden F and Cronin P: Systemic antibiotics for treating malignant wounds. Cochrane Database Syst Rev. Aug 24–2017.(Epu. View Article : Google Scholar : PubMed/NCBI
32	Schierle CF, De la Garza M, Mustoe TA and Galiano RD: Staphylococcal biofilms impair wound healing by delaying reepithelialization in a murine cutaneous wound model. Wound Repair Regen. 17:354–359. 2009. View Article : Google Scholar : PubMed/NCBI
33	Salisbury AM, Woo K, Sarkar S, Schultz G, Malone M, Mayer DO and Percival SL: Tolerance of biofilms to antimicrobials and significance to antibiotic resistance in wounds. Surg Technol Int. 33:59–66. 2018.PubMed/NCBI
34	Hughes G and Webber MA: Novel approaches to the treatment of bacterial biofilm infections. Br J Pharmacol. 174:2237–2246. 2017. View Article : Google Scholar : PubMed/NCBI
35	Villela-Castro DL, Santos VLCG and Woo K: Polyhexanide versus metronidazole for odor management in malignant (fungating) wounds: A double-blinded, randomized, clinical trial. J Wound Ostomy Continence Nurs. 45:413–418. 2018. View Article : Google Scholar : PubMed/NCBI
36	Watanabe K, Shimo A, Tsugawa K, Tokuda Y, Yamauchi H, Miyai E, Takemura K, Ikoma A and Nakamura S: Safe and effective deodorization of malodorous fungating tumors using topical metronidazole 0.75% gel (GK567): A multicenter, open-label, phase III study (RDT.07.SRE.27013). Support Care Cancer. 24:2583–2590. 2016. View Article : Google Scholar : PubMed/NCBI